Neurobehavioral Research on Infants at Risk for Language Delay and ASD
Neurobehavioral Research on Infants at Risk for Language Delay and ASD
批准号:
9055260
负责人:
CHARLES Alexander NELSON
金额:
$74.01万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2020-11-30
关键词:
AddressAgeAge-MonthsAttentionAwardBehavioralBiological MarkersBrainChildChildhoodClinicalClinical ResearchCommunication impairmentControl GroupsDevelopmentDiagnosisDiagnosticDiseaseEarly InterventionElectroencephalographyElectrophysiology (science)Employee StrikesFaceFamilyGeneral PopulationGenetic RiskGoalsInfantInterventionKnowledgeLanguageLanguage DelaysLifeMeasuresNeurodevelopmental DisorderOutcomePatternPlayPopulationPrevalencePreventive InterventionProgress ReportsRecording of previous eventsResearchResearch PersonnelRiskRisk MarkerSamplingSeveritiesSiblingsSignal TransductionSpeechSpeech DelaySymptomsTestingTimeToddlerVisitadverse outcomeautism spectrum disorderbasebehavior measurementclinically relevantclinically significantdesigneffective therapyendophenotypehigh riskhigh risk infantimprovedinstrumentlanguage impairmentneurobehavioralneurodevelopmentnovel strategiespreventpublic health relevancerelating to nervous systemscreeningsocial communicationspeech processing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Searching for biomarkers and behavioral signs of early risk for neurodevelopmental disorders has emerged as an important line of clinical research in an effort to improve diagnosis and develop the most effective treatments and preventive interventions. In our current award period we identified several significant differences
between infants at high familial risk for ASD (defined as having an older sibling with the disorder) and low risk control infants, including alterations in EEG, atypical lateralization for speech and faces, and reduced cortical connectivity all of which might serve as early risk markers. These differences were not only identified during the first year of life, their developmental trajectories were also atypical; a finding that appears to be a hallmark of risk for ASD. Our findings open up important questions about whether these risk markers extend to other infants later diagnosed with ASD, particularly infants from the general population, and whether they might also serve as risk markers for other related disorders, particularly language and social communication delay. In the next award period we address these questions by adding a new group of infants who fail a developmental screener (the CSBS) at 12 months. This group will be drawn from general pediatric practices, and will be compared to high-risk infant siblings and low risk controls on a battery of electrophysiological and behavioral measures that will be administered at 12-14 months, and again at 18, 24 and 36 months, at which time diagnostic outcomes will be evaluated. The project will address two specific aims. First, Do neural and behavioral risk markers (and their developmental trajectories) that distinguish infants at familial risk for ASD from low risk controls extend to infants at risk based on early behavioral
differences detected on a 12-month screening instrument? We hypothesize that some risk markers will be shared across both high-risk groups, though for the screened group this may only hold for infants with clinical outcomes and show different developmental trajectories. Other risk markers may be unique to infants at familial risk. Our second aim addresses the question: Do the developmental profiles of neural and behavioral risk markers we identify predict only to later diagnoses of ASD or do they extend to other non-ASD neurodevelopmental outcomes at 36 months, including language or social communication delay? We hypothesize that some of our risk markers will be shared across these non-ASD related (and overlapping) clinical outcomes, while others will be unique to ASD outcomes. As research progresses on identifying behavioral and neural markers in infants that are at risk for neurodevelopment disorders, it is critical that we extend our research beyond familial risk to the general population and to evaluate risk markers across several diagnostic outcomes. In this way our goal is to advance knowledge of the shared and unique mechanisms that can ultimately be the focus of more targeted interventions at a time when there is greatest plasticity and opportunity for preventing adverse outcomes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Predicting ASD and Other Developmental Outcomes in the First Year of Life Using EEG in a Diverse Community-based Sample (Administrative Supplement)
-
批准号:10840167
-
项目类别:
-
资助金额:$41.35万
-
财政年份:2021
-
负责人:CHARLES Alexander NELSON
-
依托单位:
Predicting ASD and Other Developmental Outcomes in the First Year of Life Using EEG in a Diverse Community-Based Sample
-
批准号:10535487
-
项目类别:
-
资助金额:$67.05万
-
财政年份:2021
-
负责人:CHARLES Alexander NELSON
-
依托单位:
Predicting ASD and other developmental outcomes in the first year of life using EEG in a diverse community-based sample
-
批准号:10360759
-
项目类别:
-
资助金额:$64.68万
-
财政年份:2021
-
负责人:CHARLES Alexander NELSON
-
依托单位:
4/5 The Cumulative Risk of Substance Exposure and Early Life Adversity on Child Health Development and Outcomes
-
批准号:9898607
-
项目类别:
-
资助金额:$29.87万
-
财政年份:2019
-
负责人:CHARLES Alexander NELSON
-
依托单位:
4/5 The Cumulative Risk of Substance Exposure and Early Life Adversity on Child Health Development and Outcomes (Administrative Supplement)
-
批准号:10373461
-
项目类别:
-
资助金额:$19.39万
-
财政年份:2019
-
负责人:CHARLES Alexander NELSON
-
依托单位:
4/5 The Cumulative Risk of Substance Exposure and Early Life Adversity on Child Health Development and Outcomes
-
批准号:10170530
-
项目类别:
-
资助金额:$19.64万
-
财政年份:2019
-
负责人:CHARLES Alexander NELSON
-
依托单位:
4/5 The Cumulative Risk of Substance Exposure and Early Life Adversity on Child Health Development and Outcomes
-
批准号:10018973
-
项目类别:
-
资助金额:$29.87万
-
财政年份:2019
-
负责人:CHARLES Alexander NELSON
-
依托单位:
Translational Post-doctoral Training in Neurodevelopment
-
批准号:9279441
-
项目类别:
-
资助金额:$14.08万
-
财政年份:2017
-
负责人:CHARLES Alexander NELSON
-
依托单位:
Translational Post-doctoral Training in Neurodevelopment
-
批准号:9918451
-
项目类别:
-
资助金额:$32.33万
-
财政年份:2017
-
负责人:CHARLES Alexander NELSON
-
依托单位:
Translational Post-doctoral Training in Neurodevelopment
-
批准号:10178112
-
项目类别:
-
资助金额:$10.42万
-
财政年份:2017
-
负责人:CHARLES Alexander NELSON
-
依托单位:
2/5-The Autism Biomarkers Consortium for Clinical Trials
-
批准号:10439669
-
项目类别:
-
资助金额:$91.4万
-
财政年份:2015
-
负责人:CHARLES Alexander NELSON
-
依托单位:
2/5-The Autism Biomarkers Consortium for Clinical Trials
-
批准号:10675093
-
项目类别:
-
资助金额:$91.2万
-
财政年份:2015
-
负责人:CHARLES Alexander NELSON
-
依托单位:
2/5-The Autism Biomarkers Consortium for Clinical Trials
-
批准号:10083889
-
项目类别:
-
资助金额:$94.85万
-
财政年份:2015
-
负责人:CHARLES Alexander NELSON
-
依托单位:
The Relation Between Early Psychosocial Deprivation and Mental Health at 12 Years
-
批准号:8272219
-
项目类别:
-
资助金额:$9.61万
-
财政年份:2010
-
负责人:CHARLES Alexander NELSON
-
依托单位:
The Relation Between Early Psychosocial Deprivation and Mental Health at 12 Years
-
批准号:7979323
-
项目类别:
-
资助金额:$59.57万
-
财政年份:2010
-
负责人:CHARLES Alexander NELSON
-
依托单位:
The Relation Between Early Psychosocial Deprivation and Mental Health at 12 Years
-
批准号:8281506
-
项目类别:
-
资助金额:$57.44万
-
财政年份:2010
-
负责人:CHARLES Alexander NELSON
-
依托单位:
The Relation Between Early Psychosocial Deprivation and Mental Health at 12 Years
-
批准号:8458977
-
项目类别:
-
资助金额:$39.21万
-
财政年份:2010
-
负责人:CHARLES Alexander NELSON
-
依托单位:
The Relation Between Early Psychosocial Deprivation and Mental Health at 12 Years
-
批准号:8130695
-
项目类别:
-
资助金额:$52.86万
-
财政年份:2010
-
负责人:CHARLES Alexander NELSON
-
依托单位:
Neurobehavioral Research on Infants at Risk for SLI and Autism
-
批准号:8096579
-
项目类别:
-
资助金额:$67.17万
-
财政年份:2009
-
负责人:CHARLES Alexander NELSON
-
依托单位:
Neurobehavioral Research on Infants at Risk for SLI and Autism
-
批准号:8490337
-
项目类别:
-
资助金额:$58.89万
-
财政年份:2009
-
负责人:CHARLES Alexander NELSON
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: